Literature DB >> 20020230

An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.

Anoop D Shah1, Andrew J B Watts, Atul B Mehta, Ashutosh D Wechalekar.   

Abstract

We report an unusual dermatological reaction to bortezomib in a 61-year-old man with AL amyloidosis. Systemic AL amyloidosis is a rare complication of monoclonal gammopathy or myeloma in which abnormally unstable free light chains cause fibrillary deposits in organs leading to multisystem disease. The treatment of AL amyloidosis is directed at the underlying plasma cell dyscrasia and most regimes have been adapted from myeloma, but drug toxicity is more common in AL amyloidosis because of the more extensive nature of the disease. We report a patient who developed asymptomatic purple discolouration of the veins of his left arm several days after receiving the infusion in his left hand, although the infusion itself had been uncomplicated with no extravasation. The discolouration resolved completely within 2 weeks; there was recurrence on a subsequent dose of bortezomib but this also subsided spontaneously. This reaction may have been transient phlebitis or a local vasogenic reaction; its transient nature and the lack of systemic features suggest it is a benign phenomenon. There appears to be no indication for discontinuation of bortezomib treatment or dose alteration in such cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20020230     DOI: 10.1007/s12185-009-0460-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

Authors:  Aldo Maria Roccaro; Teru Hideshima; Noopur Raje; Shaji Kumar; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Domenico Ribatti; Beatrice Nico; Angelo Vacca; Franco Dammacco; Paul Gerard Richardson; Kenneth Carl Anderson
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge E Romaguera; Frederick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David Schenkein; Fernando Cabanillas; Alma M Rodriguez
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

3.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Authors:  Kai Sun; Danice E C Wilkins; Miriam R Anver; Thomas J Sayers; Angela Panoskaltsis-Mortari; Bruce R Blazar; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

4.  Possible new role for NF-kappaB in the resolution of inflammation.

Authors:  T Lawrence; D W Gilroy; P R Colville-Nash; D A Willoughby
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

5.  Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Authors:  Efstathios Kastritis; Athanasios Anagnostopoulos; Maria Roussou; Savvas Toumanidis; Constantinos Pamboukas; Magdalini Migkou; Anna Tassidou; Irini Xilouri; Sossana Delibasi; Erasmia Psimenou; Sofia Mellou; Evangelos Terpos; John Nanas; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

6.  Bortezomib-induced skin eruption.

Authors:  S Sanchez-Politta; L Favet; K Kerl; P-Y Dietrich; V Piguet
Journal:  Dermatology       Date:  2008-01-23       Impact factor: 5.366

7.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

8.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Authors:  Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

10.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.

Authors:  Mario Boccadoro; Gareth Morgan; Jamie Cavenagh
Journal:  Cancer Cell Int       Date:  2005-06-01       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.